-
公开(公告)号:CO5011122A1
公开(公告)日:2001-02-28
申请号:CO99024047
申请日:1999-04-21
Applicant: ABBOTT LAB
Inventor: MARING J CLARENE , VINVENT L GIRANDA , KRUEGER ALLAN C , MUCHMORE STEVEN W , VINVENT S STOLL , SHELDON WANG , MING C YEUNG , FLOSI WILLIAM J , YU-GUI GU , WARREN M KATI , ZHEN LI , MINGHUA SUN , YIBO XU , MCDANIEL KEITH F , HUI-JU CHEN , DEGOEY DAVID A , YUANWEI CHEN , KEMPF DALE J , MADIGAN DAROLD L , KENT D STEWART , WANG GARY T , CHEN ZHAO , KLEIN LARRY L , GRAMPOVNIK DAVID J
IPC: A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/445 , A61K31/5377 , A61P31/16 , A61P43/00 , C07D207/16 , C07D207/32 , C07D207/325 , C07D207/327 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/572
Abstract: Un compuesto de la fórmula:ó una sal, éster o precursor de droga farmacéuticamente aceptable de éste,en donde:R1 se selecciona del grupo conformado por:(a) -CO2 H, (b) -CH2 CO2 H, (c) -SO3 H, (d) -CH2 SO3 H, (e) -SO2 H, (f) -CH2 SO2 H, (g) -PO3 H2 , (h) -CH2 PO3 H2 , (i) -PO2 H, (j) -CH2 PO2 H, (k) tetrazolil, (l) -CH2 -tetrazolil, (m) -C(=O)-NH-S(O)2 -R11 ,(n) -CH2 C(=O)-NH- S(O)2 -R11 (o) -SO2 N(T-R11 )R12 y (p) -CH2 SO2 N(T-R11 )R12 en donde T se selecciona del grupo conformado por(i) un enlace, (ii) -C(=O)-, (iii) -C(=O)O-, (iv) -C(=O)S-, y (v) -C(=O)NR36 -, (vi) -C(=S)O-, (vii) -C(=S)S-, y (viii) -C(=S)NR36 -,R11 se selecciona del grupo conformado por(i) alquil C1 -C12 , (ii) alquenil C2 -C12 , (iii) cicloalquil, (iv) (cicloalquil)alquil, (v) (cicloalquil)alquenil, (vi) cicloalquenil, (vii) (cicloalquenil)alquil, (viii) (cicloalquenil)alquenil, (ix) aril, (x) (aril)alquil, (xi) (aril)alquenil, (xii) heterocíclico, (xiii) (heterocíclico)alquil y (xiv) (heterocíclico)alquenil; yR12 y R36 se seleccionan independientemente del grupo conformado por(i) hidrógeno, (ii) alquil C1 -C12 , (iii) alquenil C2 -C12 , (iv) cicloalquil, (v) (cicloalquil)alquil,(vi) (cicloalquil)alquenil, (vii) cicloalquenil,(viii) (cicloalquenil)alquil, - 2 -(ix) (cicloalquenil)alquenil, (x) aril, (xi) (aril)alquil, (xii) (aril)alquenil,(xiii) heterocíclico, (xiv) (heterocíclico)alquil y(xv) (heterocíclico)alquenil;X se selecciona del grupo conformado por(a) C(=O)-N(R* )-, (b) N(R* )-C(=O)-, (c) C(=S)-N(R* )-, (d) N(R* )-C(=S)-, (e) N(R* )-SO2 -, y (f) SO2 -N(R* )- en donde R* es hidrógeno, alquil de cadena corta C1 -C3 ó ciclopropil;R2 se selecciona del grupo conformado por(a) hidrógeno, (b) alquil C1 -C6 , (c) alquenil C2 -C6 , (d) cicloalquil C3 -C6 , (e) cicloalquenil C5 -C6 , (f) haloalquil C1 -C6 y (g) haloalquenil C2 -C6 ; ó R2 -X- esen donde Y1 es -CH2 -, -O-, -S- ó -NH- y Y2 es -C(=O)- ó -C(Raa )(Rbb ) en donde Raa y Rbb son independientemente seleccionados del grupo conformado por hidrógeno, alquil de cadena corta C1 -C3 , hidroximetil, 1-hidroxietil, 2-hidroxietil, aminometil, 1-aminoetil, 2-aminoetil, tiolmetil, 1-tioletil, 2-tioletil, metoximetil, N-metilaminometil y metiltiometil;R3 y R4 son independientemente seleccionados del grupo conformado por(a) hidrógeno, (b) cicloalquil, (c) cicloalquenil (d) heterocíclico, (e) aril y (f) AND#8209;ZAND#8209;R14en donde Z es (i) -C(R37a )(R37b )AND#8209; (ii) AND#8209;C(R47 )=C(R48 )AND#8209;, (iii) AND#8209;CºCAND#8209;, (iv) AND#8209;C(=O)AND#8209;, (v) AND#8209;C(=S)AND#8209;, (vi) AND#8209;C(=NR15 )AND#8209;, (vii) -C(R37a )(OR37c )-, (viii) -C(R37a )(SR37c )AND#8209;, (ix) AND#8209;C(R37a )(N(R37b )(R37c )), (x) AND#8209;C(R37a )(R37b )-O-, (xi) AND#8209;C(R37a )(R37b )-N(R37c )-, (xii) -C(R37a )(R37b )AND#8209;N(O)(R37c )AND#8209;,(xiii) AND#8209;C(R37a )(R37b )AND#8209;N(OH)AND#8209;, (xiv) AND#8209;C(R37a )(R37b )AND#8209;SAND#8209;, (xv) AND#8209;C(R37a )(R37b )AND#8209;S(O)AND#8209;, (xvi) AND#8209;C(R37a )(R37b )AND#8209;S(O)2 AND#8209;,(xvii) -C(R37a )(R37b )AND#8209;C(=O)AND#8209;, (xviii) AND#8209;C(R37a )(R37b )AND#8209;C(=S)-, (xix) AND#8209;C(R37a )(R37b )AND#8209;C(=NR15 )AND#8209;,(xx) AND#8209;C(R37a )(OR37c )AND#8209;C(=O)AND#8209;,(xxi) AND#8209;C(R37a )(SR37c )AND#8209;C(=O),(xxii) AND#8209;C(R37a )(OR37c )C(=S)AND#8209;,(xxiii) C(R37a )(SR37c )AND#8209;C(=S)AND#8209;,(xxiv) AND#8209;C(=O)AND#8209;C(R37a )(OR37c )-,(xxv) -C(=O)AND#8209;C(R37a )(SR37c )-,(xxvi) AND#8209;C(=S)AND#8209;C(R37a )(OR37c )-,(xxvii) AND#8209;C(=S)AND#8209;C(R37a )(SR37c )AND#8209;(xxviii) -C(R37a )(OR37c )AND#8209;C(R37a )(OR37c )-,(xxix) -C(37a )(SR37c )-C(R37a )(OR37c )-,(xxx) -C(R37a )(OR37c )-C(R37a )(SR37c )-,(xxxi) -C(R37a )(SR37c )-C(R37a )(SR37c )-,(xxxii) AND#8209;C(=O)AND#8209;C(=O)AND#8209;, (xxxiii)AND#8209;C(=S)AND#8209;C(=S)AND#8209;,(xxxiv) AND#8209;C(=O)AND#8209;OAND#8209;, (xxxv) AND#8209;C(=O)AND#8209;SAND#8209;,(xxxvi) AND#8209;C(=S)AND#8209;OAND#8209;, (xxxvii) AND#8209;C(=S)AND#8209;SAND#8209;,(xxxviii) AND#8209;C(=O)AND#8209;N(R37a )AND#8209;, (xxxix) AND#8209;C(=S)AND#8209;N(R37a )-,(xl) AND#8209;C(R37a )(R37b )AND#8209;C(=O)AND#8209;N(R37a )-,(xli) AND#8209;C(R37a )(R37b )AND#8209;C(=S)AND#8209;N(R37a )-,(xlii) AND#8209;C(R37a )(R37b )AND#8209;C(=O)-O-,(xliii) AND#8209;C(R37a )(R37b )AND#8209;C(=O)-S-,(xliv) AND#8209;C(R37a )(R37b )AND#8209;C(=S)-O-,(xlv) AND#8209;C(R37a )(R37b )AND#8209;C(=S)AND#8209;SAND#8209;,(xlvi ) AND#8209;C(R37a )(R37b )-N(R37b )-C(=O)-,(xlvii) C(R37a )(R37b )-N(R37b )-C(=S)-,(xlviii) AND#8209;C(R37a )(R37b )-O-C(=O)-,(xlix) AND#8209;C(R37a )(R37b )-S-C(=O)-,(l) -C(R37a )(R37b )-O-C(=S)AND#8209;,(li) -C(R37a )(R37b )-S-C(=S)AND#8209;,(lii) -C(R37a )(R37b )AND#8209;N(R37b )AND#8209;C(=O)AND#8209;N(R37a )-,(liii) C(R37a )(R37b )-N(R37a )-C(=S)AND#8209;N(R37a )-,(liv) AND#8209;C(R37a )(R37b )AND#8209;N(R37b )AND#8209;C(=O)AND#8209;OAND#8209;,(lv) AND#8209;C(R37a )(R37b )AND#8209;N(R37b )AND#8209;C(=O)AND#8209;SAND#8209;,(Ivi) AND#8209;C(R37a )(R37b )AND#8209;N(R37b )AND#8209;C(=S)AND#8209;OAND#8209;,(lvii) AND#8209;C(R37a )(R37b )N(R37b )-C(=S)-S-,(lviii) AND#8209;C(R37a )(R37b )AND#8209;OAND#8209;C(=O)AND#8209;N(R37a )-,(lix) AND#8209;C(R37a )(R37b )AND#8209;SAND#8209;C(=O)AND#8209;N(R37a )-,(lx) AND#8209;C(R37a )(R37b )-O-C(=S)AND#8209;N(R37a )-,(lxi) -C(R37a )(R37b )AND#8209;SAND#8209;C(=S)AND#8209;N(R37a )-,(lxii) AND#8209;C(R37a )(R37b )AND#8209;OAND#8209;C(=O)-O-,(lxiii) AND#8209;C(R37a )(R37b )AND#8209;SAND#8209;C(=O)-O-,(lxiv) -C(R37a )(R37b )AND#8209;OAND#8209;C(=O)-S-,(lxv) -C(R37a )(R37b )AND#8209;SAND#8209;C(=O)AND#8209;SAND#8209;,(lxvi) AND#8209;C(R37a )(R37b )AND#8209;OAND#8209;C(=S)AND#8209;OAND#8209;, (lxvii) AND#8209;C(R37a )(R37b )AND#8209;SAND#8209;C(=S)AND#8209;OAND#8209;,(lxviii) AND#8209;C(R37a )(R37b )AND#8209;OAND#8209;C(=S)AND#8209;OAND#8209;,(lxix) -C(R37a )(R37b )AND#8209;SAND#8209;C(=S)AND#8209;SAND#8209; ó(lxx) -C(R37a )(R37b )AND#8209;C(R37a )(OR37c )AND#8209;; y en dondeR14 es(i) hidrógeno, (ii) alquil C1 AND#8209;C12 , (iii) haloalquil, (iv) hidroxialquil, (v) alquil sustituido con tiol, (vi) alquil sustituidocon AND#8209;R37 CO, (vii) alquil sustituido con AND#8209;R37 CS, (viii) aminoalquil, (ix) alquil sustituido con AND#8209;(R37c )AND#8209;NH, (x) alquil sustituido con AND#8209;(R37a )(R37c )N, (xi) alquil sustituido conAND#8209;R37a OAND#8209;(O=)C, (xii) alquil sustituido con AND#8209;R37a SAND#8209;(O=)C, (xiii) alquil sustituido con AND#8209;R37a OAND#8209;(S=)C, (xiv) alquil sustituido con AND#8209;R37a SAND#8209;(S=)C, (xv) alquil sustituido con AND#8209;(R37a O)2 AND#8209;P(=O), (xvi) cianoalquil, (xvii) alquenil C2 AND#8209;C12 , (xviii) haloalquenil, (xix) alquinil C2 AND#8209;C12 ,(xx) cicloalquil, (xxi) (cicloalquil)alquil, (xxii) (cicloalquil)alquenil, (xxiii) (cicloalquil)alquinil, (xxiv) cicloalquenil,(xxv) (cicloalquenil)alquil, (xxvi) (cicloalquenil)alquenil,(xxvii) (cicloalquenil)alquinil, (xxviii) aril,(xxix) (aril)alquil, (xxx) (aril)alquenil, (xxxi) (aril)alquinil, (xxxii) heterocíclico, (xxxiii) (heterocíclico)alquil, (xxxiv) (heterocíclico)alquenil ó (xxxv) (heterocíclico)alquinil,con la condición de que R14 sea diferente a hidrógeno cuando Z sea AND#8209;C(R37a )(R37b )AND#8209;N(R37b )-C(=O)-O-,-C(R37a )R37b )-N(R37b )-C(=S)-O-,-(CR37a )(R37b )-N(R37b )-C(=O)-S-,-C(R37a )(R37b )-N(R37b )-C(=S)-S-, -C(R37a )(R37b )AND#8209;O-C(=O)-O-, -C(R37a )(R37b )-O-C(=S)-O-, -C(R37a )(R37b )AND#8209;SAND#8209;C(=O)AND#8209;O, AND#8209;C(R37a )(R37b )-S-C(=S)-O-,-C(R37a )(R37b )-O-C(=O)-SAND#8209;, AND#8209;C(R37a )(R37b )AND#8209;OAND#8209;C(=S)AND#8209;SAND#8209;,AND#8209;C(R37a )(R37b )AND#8209;SAND#8209;C(=O)AND#8209;SAND#8209;, ó AND#8209;C(R37a )(R37b )AND#8209;S-C(=S)-S-;R37a , R37b , R47 , y R48 en cada ocurrencia se seleccionan independientemente del grupo conformado por:(i) hidrógeno, (ii) alquil C1 AND#8209;C12 , (iii) haloalquil, (iv) hidroxialquil, (v) alcoxialquil, (vi) alquenil C2 AND#8209;C12 ,(vii) haloalquenil, (viii) alquinil C2 AND#8209;C12 , (ix) cicloalquil, (x) (cicloalquil)alquil, (xi) (cicloalquil)alquenil,(xii) (cicloalquil)alquinil, (xiii) cicloalquenil,(xiv) (cicloalquenil)alquil, (xv) (cicloalquenil)alquenil,(xvi) (cicloalquenil)alquinil, (xvii) aril, (xviii) (aril)alquil, (xix) (aril)alquenil, (xx) (aril)alquinil, (xxi) heterocíclico,(xxii) (heterocíclico)alquil, (xxiii) (heterocíclico)alquenil y(xxiv) (heterocíclico)alquinil;R37c en cada ocurrencia se selecciona independientemente del grupo conformado por:(i) hidrógeno, (ii) alquil C1 AND#8209;C12 , (iii) haloalquil, (iv) alquenil C2 AND#8209;C12 , (v) haloalquenil, (vi) alquinil C2 AND#8209;C12 ,(vii) cicloalquil, (viii) (cicloalquil)alquil,(ix) (cicloalquil)alquenil, (x) (cicloalquil)alquinil,(xi) cicloalquenil, (xii) (cicloalquenil)alquil,(xiii) (cicloalquenil)alquenil,(xiv) (cicloalquenil)alquinil, (xv) aril, (xvi) (aril)alquil, (xvii) (aril)alquenil,(xviii) (aril)alquinil, (xix) heterocíclico,(xx) (heterocíclico)alquil, (xxi) (heterocíclico)alquenil,(xxii) (heterocíclico)alquinil, (xxiii) AND#8209;C(=O)AND#8209;R14 ,(xxiv) AND#8209;C(=S)AND#8209;R14 , (xxv) AND#8209;S(O)2 AND#8209;R14 y (xxvi) hidroxialquil; óen caso de que Z sea AND#8209;C(R37a )(R37b )AND#8209;N(R37c ), entonces N(R37c ) y R14 tomados en conjunto forman un grupo azido;óen caso de que Z sea AND#8209;(R37a )(R37b )AND#8209;N(O)(R37c )AND#8209;, entonces N(O)(R37c ) y R14 tomados en conjunto forman un anillo heterocíclico NAND#8209;oxidado de 3 AND#8209; 7 miembros que tiene por lo menos un átomo de nitrógeno en el anillo NAND#8209;oxidadoóen caso de que Z sea AND#8209;C(R37a )(OR37c ), AND#8209;C(R37a )(SR37c ) ó C(R37a )(N(R37b )(R37c ))AND#8209;, entonces R37a , R14 y el átomo de carbono alcual van ligados, tomados en conjunto forman un anillo ciclopentil, ciclopentenil, ciclohexil ó ciclohexenil;R15 se selecciona del grupo conformado por:(i) hidrógeno, (ii) hidroxi, (iii) amino, (iv) alquil C1 AND#8209;C12 , (v) haloalquil, (vi) alquenil C
-
公开(公告)号:NO20005301A
公开(公告)日:2000-12-08
申请号:NO20005301
申请日:2000-10-20
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GU YU-GUI , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , KATI WARREN M , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , LIN ZHEN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , STOLL VINCENT S , SUN MINGHUA , WANG GARY T , WANG SHELDON , XU YIBO , YEUNG MING C , ZHAO CHEN , KENNEDY APRIL
IPC: A61K31/401 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/5377 , A61P31/16 , A61P43/00 , C07D207/16 , C07D207/32 , C07D207/325 , C07D207/327 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/572 , A61K31/40
CPC classification number: C07D207/327 , C07D207/16 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D403/04 , C07D405/04 , C07D405/06 , C07D409/06 , C07D413/04 , C07D417/04 , C07D417/06 , C07F9/5722
-
公开(公告)号:NO20005301D0
公开(公告)日:2000-10-20
申请号:NO20005301
申请日:2000-10-20
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GU YU-GUI , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , KATI WARREN M , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , LIN ZHEN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , STOLL VINCENT S , SUN MINGHUA , WANG GARY T , WANG SHELDON , XU YIBO , YEUNG MING C , ZHAO CHEN , KENNEDY APRIL
IPC: A61K31/401 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/5377 , A61P31/16 , A61P43/00 , C07D207/16 , C07D207/32 , C07D207/325 , C07D207/327 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/572 , C07D
-
公开(公告)号:AU3554599A
公开(公告)日:1999-11-08
申请号:AU3554599
申请日:1999-04-12
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GU YU-GUI , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GIRANDA VINCENT L , GRAMPOVNIK DAVID J , KATI WARREN M , KEMPF DALE J , KLEIN LARRY L , KRUEGER ALLAN C , LIN ZHEN , MADIGAN DAROLD L , MCDANIEL KEITH F , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , STOLL VINCENT S , SUN MINGHUA , WANG GARY T , WANG SHELDON , XU YIBO , YEUNG MING C , ZHAO CHEN , KENNEDY APRIL
IPC: A61K31/401 , A61K31/4025 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/5377 , A61P31/16 , A61P43/00 , C07D207/16 , C07D207/32 , C07D207/325 , C07D207/327 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/572 , A61K31/40 , C07D407/04
-
公开(公告)号:ZA201101558B
公开(公告)日:2018-11-28
申请号:ZA201101558
申请日:2011-02-28
Applicant: ABBOTT LAB , ENANTA PHARM INC
Inventor: ENGSTROM KEN , GRIEME TIM , WAGAW SABLE H , CHEN HUI-JU , KU YIYIN , MEI JIANZHANG , GAI YONGHUA , LIU DONG , OR YAT SUN , SHANLEY JASON P , GRAMPOVNIK DAVID J , SUN YING , SHEIKH AHMAD , MCDANIEL KEITH F , KEMPF DALE J
Abstract: The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
-
公开(公告)号:CA2736895C
公开(公告)日:2016-02-09
申请号:CA2736895
申请日:2009-09-10
Applicant: ENANTA PHARM INC , ABBOTT LAB
Inventor: KU YIYIN , MCDANIEL KEITH F , CHEN HUI-JU , SHANLEY JASON P , KEMPF DALE J , GRAMPOVNIK DAVID J , SUN YING , LIU DONG , GAI YONGHUA , OR YAT SUN , WAGAW SABLE H , ENGSTROM KEN , GRIEME TIM , SHEIKH AHMAD , MEI JIANZHANG
IPC: C07D487/04 , A61K31/473 , A61K31/498 , A61K31/501 , A61K31/506 , A61P31/14
Abstract: The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
-
公开(公告)号:GT201100056AA
公开(公告)日:2014-09-26
申请号:GT201100056
申请日:2011-03-28
Applicant: ENANTA PHARM INC , ABBOTT LAB
Inventor: KU YIYIN , MCDANIEL KEITH F , CHEN HUI-JU , SHANLEY JASON P , KEMPF DALE J , GRAMPOVNIK DAVID J , SUN YING , LIU DONG , GAI YONGHUA , OR SUN YAY , WAGAW SABLE H , ENGSTROM KEN , GRIEME TIM , SHEIK AHMAD , MEI JIANZHANG
Abstract: LA PRESENTE INVENCIÓN SE RELACIONA CON MACROCICLOS NOVEDOSOS QUE POSEEN ACTIVIDAD CONTRA EL VIRUS DE LA HEPATITIS C (HCV) Y SON ÚTILES EN EL TRATAMIENTO DE LAS INFECCIONES POR HCV. MAS PARTICULARMENTE, LA INVENCIÓN SE RELACIONA CON NUEVOS COMPUESTOS MACROCÍCLICOS, CON COMPOSICIONES QUE CONTIENEN DICHOS COMPUESTOS Y MÉTODOS PARA USAR LOS MISMOS Y TAMBIÉN CON PROCESOS PARA OBTENER DICHOS COMPUESTOS
-
公开(公告)号:UA103054C2
公开(公告)日:2013-09-10
申请号:UAA201104324
申请日:2009-09-10
Applicant: ENANTA PHARM INC , ABBOTT LAB
Inventor: KU YIYIN , MCDANIEL KEITH F , CHEN HUI-JU , SHANLEY JASON P , KEMPF DALE J , GRAMPOVNIK DAVID J , SUN YING , LIU DONG , GAI YONGHUA , OR YAT SUN , WAGAW SEBLE H , ENGSTROM KEN , GRIEME TIM , SHEIKH AHMAD , MEI JIANZHANG
Abstract: Данноеизобретениекасаетсяновыхмакроциклическихсоединенийи ихприменения.Данноеизобретениедополнительнокасаетсяфармацевтическихкомпозиций, которыесодержатсоединения, описанныев данномизобретении, илиихфармацевтическиприемлемыесоли, сложныеэфирыилипролекарстсвенныесредства, всочетаниис фармацевтическиприемлемымносителемилиэксципиентом.
-
公开(公告)号:NZ592170A
公开(公告)日:2013-02-22
申请号:NZ59217009
申请日:2009-09-10
Applicant: ABBOTT LAB , ENANTA PHARJMACEUTICALS INC
Inventor: KU YIYIN , MCDANIEL KEITH F
Abstract: 592170 Disclosed is a compound of formula I or 1' e.g. tert-butyl (2R,6S, 13aS, 14aR, 16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-5, 16-dioxo-2-(phenanthridin-6-y1oxy)-1,2,3,S,6,7,8,9,10,11, 13a,14,14a,15,16,16a hexadecahydrocyclopropa[e]pyrro[1,2-a][1,4]diazacyclopentadecin-6-ylcarbamate or a pharmaceutically acceptable salt thereof, wherein the variables are defined in the specification.
-
公开(公告)号:CA2504385C
公开(公告)日:2012-12-18
申请号:CA2504385
申请日:2003-10-31
Applicant: ABBOTT LAB
Inventor: PRATT JOHN K , BETEBENNER DAVID A , DONNER PAMELA L , GREEN BRIAN E , KEMPF DALE J , MCDANIEL KEITH F , MARING CLARENCE J , STOLL VINCENT S , ZHANG RONG
IPC: C07D495/04 , A61K31/554 , A61P31/00 , C07D213/69 , C07D215/22 , C07D401/04 , C07D417/04 , C07D417/14 , C07D471/04 , C07D513/04 , C07D513/14 , C07D519/00
Abstract: The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided.
-
-
-
-
-
-
-
-
-